Human Longevity IPO
Human Longevity Inc. (HLI) is a genomics and precision medicine company that combines large-scale genomic sequencing with machine learning to advance health and longevity research. The company focuses on understanding human aging and developing personalized medicine approaches. Investors are interested in HLI's innovative approach to genomics and its potential in the growing precision medicine market.
Key Facts
| Industry | Biotechnology |
| Founded | 2013 |
| Headquarters | San Diego, CA |
| Employees | ~200 |
| Website | humanlongevity.com |
| Funding | Series B. Total raised: ~$300M |
About Human Longevity
Human Longevity Inc. (HLI) combines genomics, advanced clinical testing, and machine learning to provide comprehensive health assessments and precision medicine solutions. The company operates high-end health centers that offer extensive diagnostic services, including whole genome sequencing, advanced imaging, and comprehensive biomarker analysis. HLI's approach integrates massive amounts of individual health data to identify disease risks and optimize health outcomes before symptoms appear.
Founded by genomics pioneer Craig Venter, HLI focuses on extending healthy human lifespan through early detection and prevention of age-related diseases. The company's Health Nucleus centers provide ultra-comprehensive health assessments that go far beyond traditional annual physicals, incorporating cutting-edge diagnostics and personalized health recommendations. While HLI's services target affluent individuals who can afford premium healthcare, the company's research and data collection efforts aim to advance precision medicine and longevity science more broadly.
IPO Status
Human Longevity Inc. has not announced any IPO plans or filed public offering documents. The company has gone through various funding rounds and strategic changes since its founding, focusing on genomics research and precision medicine applications. As a biotechnology and genomics company, HLI operates in a sector where IPO timing often depends on clinical milestones, regulatory progress, and market conditions for biotech offerings. No confirmed details about IPO preparations, timeline, or valuation targets have been disclosed. The company continues to pursue its research and commercial activities as a private entity.
Competitors
Frequently Asked Questions
Does Human Longevity have a stock?
No, Human Longevity Inc. has not had an IPO and remains a private company. The company has not announced any plans to go public currently.
When is the Human Longevity IPO date?
Human Longevity has not announced an IPO date or disclosed any timeline for a potential public offering. Biotech IPO timing often depends on clinical and regulatory milestones.
How can I buy Human Longevity stock?
Human Longevity stock is not available for public purchase as the company is privately held. Shares would become available only if and when the company decides to go public.
Stay Updated on the Human Longevity IPO
Get real-time alerts when Human Longevity files for an IPO, prices shares, or begins trading.
Get IPO Alerts